# US 2019/0375735 A1 · HDAC6 Selective Inhibitors, Preparation Method Therefor, and Application Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375735 A1
- Document ID: US20190375735A1
- Status: Published application
- Kind: A1
- Application number: 16/476,660
- Filed: 2018-01-10
- Published: 2019-12-12
- Earliest claimed: 2017-01-10
- Assignees: Cstone Pharmaceuticals (Suzhou) Co., Ltd.; Cstone Pharmaceuticals (Shanghai) Co., Ltd.; Cstone Pharmaceuticals
- Applicants: Cstone Pharmaceuticals (Suzhou) Co., Ltd.; Cstone Pharmaceuticals (Shanghai ) Co., Ltd; Cstone Pharmaceuticals
- Inventors: Hao Wu; Changqing Wei; Qiang Guo; Guifen Zhang; Bin Liu; Yonggang Liao; Yao Xiao; Shuhui Chen
- Web page: https://patentgrep.com/patent/US20190375735A1

## CPC

- C07D 307/16: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 405/14: containing three or more hetero rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/69: Boron compounds
- A61P 35/00: Antineoplastic agents
- C07D 307/06: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound represented by formula (I), a pharmaceutically acceptable salt or a isomer thereof,
is a single bond or a double bond;
n is 0 or 1;
each of T1, T2 is independently selected from the group consisting of CH, CH2, —C(═O)— and N;
T3 is C or N;
each of Z1, Z2, Z3 is independently CH or N;
L1 is selected from the group consisting of a single bond, —NH— and —C(═O)—NH—;
R1 is selected from the group consisting of C1-3 alkyl, phenyl or 6-membered heteroaryl, each of which is optionally substituted by 1, 2 or 3 R;
R2 is —H, F, Cl, Br or I;
Ring A is 4 to 7-membered heterocycloalkyl;
R is F, Cl, Br or I;
the “hetero” in 6-membered heteroaryl or 4 to 7-membered heterocycloalkyl is independently —NH—, N or —O—;
in any of the cases above, the number of heteroatom or heteroatom group is independently 1, 2 or 3, respectively.

### Claim 2 (depends on 1)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 1, wherein R1 is selected from the group consisting of methyl, ethyl, isopropyl, phenyl and pyridyl, each of which is optionally substituted by 1, 2 or 3 R; or, ring A is selected from the group consisting of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolanyl, 1,4-dioxepinyl, 1,4-dioxanyl, 1,4-oxazacycloheptyl and morpholinyl; or, the structural unit

### Claim 3 (depends on 2)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 2, wherein R1 is selected from the group consisting of CH3,
each of which is optionally substituted by 1, 2 or 3 R; or, ring A is selected from the group consisting of
or, the structural unit

### Claim 4 (depends on 3)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 3, wherein R1 is selected from the group consisting of CH3,

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 3)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 3, wherein the structural unit

### Claim 10 (depends on 1)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 1, wherein the structural unit
or, the structural unit
is selected from the group consisting of —CH2—, —NH—, —C(═O)—NH—,
or, the structural unit

### Claim 11 (depends on 10)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 10, wherein the structural unit

### Claim 12 (depends on 11)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 11, wherein the structural unit
is selected from the group consisting of

### Claim 13 (depends on 12)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 12, wherein the structural unit
is selected from the group consisting of

### Claim 14 (depends on 1)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 1, wherein the structural unit
is selected from the group consisting of

### Claim 15 (depends on 14)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 14, wherein the structural unit
is selected from the group consisting of

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 1, wherein the structural unit

### Claim 19 (depends on 1)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 1, which is selected from the group consisting of
wherein, ring A, R, R2, L1 and n is as defined in claim 1;
R1 is as defined in claim 1.

### Claim 20 (depends on 1, 19)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 19, which is
wherein,
each of E1, E2 is independently —O—, —CH2— or —CH2—CH2—;
R, R2, L1 and n is as defined in claim 1.

### Claim 21

The compounds or the pharmaceutically acceptable salt thereof, which is selected from the group consisting of

### Claim 22 (depends on 21)

The compound, the pharmaceutically acceptable salt or the isomer thereof as defined in claim 21 is selected from the group consisting of

### Claim 23 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof as defined in claim 1 as an active ingredient, as well as a pharmaceutically acceptable carrier.

### Claim 24 (depends on 1)

A method for treating HDAC6 related diseases in a subject in need thereof, comprising administering a pharmaceutically effective amount of the compound or the pharmaceutically acceptable salt thereof defined in claim 1 to the subject.

### Claim 25 (depends on 24)

The method defined in the claim 24, which is characterized by the medicament is for treating multiple myeloma.

### Claim 26 (depends on 23)

A method for treating HDAC6 related diseases in a subject in need thereof, comprising administering a pharmaceutically effective amount of the composition defined in claim 23 to the subject.
